Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat

P. Rajab, J. Fox, S. Riaz, D. Tomlinson, D. Ball, P. L. Greenhaff

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Prolonged treatment with the β2-adrenoceptor agonist clenbuterol (1-2 mg·kg body mass-1·day -1) is known to induce the hypertrophy of fast-contracting fibers and the conversion of slow- to fast-contracting fibers. We investigated the effects of administering a lower dose of clenbuterol (250 μg·kg body mass-1·day -1) on skeletal muscle myosin heavy chain (MyHC) protein isoform content and adenine nucleotide (ATP, ADP, and AMP) concentrations. Male Wistar rats were administered clenbuterol (n = 8) or saline (n = 6) subcutaneously for 8 wk, after which the extensor digitorum longus (EDL) and soleus muscles were removed. We demonstrated an increase of type IIa MyHC protein content in the soleus from ~0.5% in controls to ~18% after clenbuterol treatment (P < 0.05), which was accompanied by an increase in the total adenine nucleotide pool (TAN; ~19%, P < 0.05) and energy charge [E-C = (ATP + 0.5 ADP)/(ATP + ADP + AMP); ~4%; P < 0.05]. In the EDL, a reduction in the content of the less prevalent type I MyHC protein from ~3% in controls to 0% after clenbuterol treatment (P < 0.05) occurred without any alterations in TAN and E-C. These findings demonstrate that the phenotypic changes previously observed in slow muscle after clenbuterol administration at 1-2 mg·kg body mass-1·day-1 are also observed at a substantially lower dose and are paralleled by concomitant changes in cellular energy metabolism.

Original languageEnglish
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume279
Issue number3 48-3
Publication statusPublished - 2000

Fingerprint

Skeletal Muscle Myosins
Clenbuterol
Myosin Heavy Chains
Energy Metabolism
Protein Isoforms
Triacetoneamine-N-Oxyl
Adenosine Diphosphate
Adenine Nucleotides
Adenosine Triphosphate
Adenosine Monophosphate
Adrenergic Receptors
Hypertrophy
Wistar Rats
Skeletal Muscle
Proteins
Muscles

Keywords

  • β-Adrenoceptor agonist
  • Adenosine 5'-triphosphate
  • Energy charge
  • Myosin heavy chain protein composition

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. / Rajab, P.; Fox, J.; Riaz, S.; Tomlinson, D.; Ball, D.; Greenhaff, P. L.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 279, No. 3 48-3, 2000.

Research output: Contribution to journalArticle

@article{98cd34a2a4924601a3ac6d4866b3cdcb,
title = "Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat",
abstract = "Prolonged treatment with the β2-adrenoceptor agonist clenbuterol (1-2 mg·kg body mass-1·day -1) is known to induce the hypertrophy of fast-contracting fibers and the conversion of slow- to fast-contracting fibers. We investigated the effects of administering a lower dose of clenbuterol (250 μg·kg body mass-1·day -1) on skeletal muscle myosin heavy chain (MyHC) protein isoform content and adenine nucleotide (ATP, ADP, and AMP) concentrations. Male Wistar rats were administered clenbuterol (n = 8) or saline (n = 6) subcutaneously for 8 wk, after which the extensor digitorum longus (EDL) and soleus muscles were removed. We demonstrated an increase of type IIa MyHC protein content in the soleus from ~0.5{\%} in controls to ~18{\%} after clenbuterol treatment (P < 0.05), which was accompanied by an increase in the total adenine nucleotide pool (TAN; ~19{\%}, P < 0.05) and energy charge [E-C = (ATP + 0.5 ADP)/(ATP + ADP + AMP); ~4{\%}; P < 0.05]. In the EDL, a reduction in the content of the less prevalent type I MyHC protein from ~3{\%} in controls to 0{\%} after clenbuterol treatment (P < 0.05) occurred without any alterations in TAN and E-C. These findings demonstrate that the phenotypic changes previously observed in slow muscle after clenbuterol administration at 1-2 mg·kg body mass-1·day-1 are also observed at a substantially lower dose and are paralleled by concomitant changes in cellular energy metabolism.",
keywords = "β-Adrenoceptor agonist, Adenosine 5'-triphosphate, Energy charge, Myosin heavy chain protein composition",
author = "P. Rajab and J. Fox and S. Riaz and D. Tomlinson and D. Ball and Greenhaff, {P. L.}",
year = "2000",
language = "English",
volume = "279",
journal = "American Journal of Physiology-Regulatory Integrative and Comparative Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "3 48-3",

}

TY - JOUR

T1 - Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat

AU - Rajab, P.

AU - Fox, J.

AU - Riaz, S.

AU - Tomlinson, D.

AU - Ball, D.

AU - Greenhaff, P. L.

PY - 2000

Y1 - 2000

N2 - Prolonged treatment with the β2-adrenoceptor agonist clenbuterol (1-2 mg·kg body mass-1·day -1) is known to induce the hypertrophy of fast-contracting fibers and the conversion of slow- to fast-contracting fibers. We investigated the effects of administering a lower dose of clenbuterol (250 μg·kg body mass-1·day -1) on skeletal muscle myosin heavy chain (MyHC) protein isoform content and adenine nucleotide (ATP, ADP, and AMP) concentrations. Male Wistar rats were administered clenbuterol (n = 8) or saline (n = 6) subcutaneously for 8 wk, after which the extensor digitorum longus (EDL) and soleus muscles were removed. We demonstrated an increase of type IIa MyHC protein content in the soleus from ~0.5% in controls to ~18% after clenbuterol treatment (P < 0.05), which was accompanied by an increase in the total adenine nucleotide pool (TAN; ~19%, P < 0.05) and energy charge [E-C = (ATP + 0.5 ADP)/(ATP + ADP + AMP); ~4%; P < 0.05]. In the EDL, a reduction in the content of the less prevalent type I MyHC protein from ~3% in controls to 0% after clenbuterol treatment (P < 0.05) occurred without any alterations in TAN and E-C. These findings demonstrate that the phenotypic changes previously observed in slow muscle after clenbuterol administration at 1-2 mg·kg body mass-1·day-1 are also observed at a substantially lower dose and are paralleled by concomitant changes in cellular energy metabolism.

AB - Prolonged treatment with the β2-adrenoceptor agonist clenbuterol (1-2 mg·kg body mass-1·day -1) is known to induce the hypertrophy of fast-contracting fibers and the conversion of slow- to fast-contracting fibers. We investigated the effects of administering a lower dose of clenbuterol (250 μg·kg body mass-1·day -1) on skeletal muscle myosin heavy chain (MyHC) protein isoform content and adenine nucleotide (ATP, ADP, and AMP) concentrations. Male Wistar rats were administered clenbuterol (n = 8) or saline (n = 6) subcutaneously for 8 wk, after which the extensor digitorum longus (EDL) and soleus muscles were removed. We demonstrated an increase of type IIa MyHC protein content in the soleus from ~0.5% in controls to ~18% after clenbuterol treatment (P < 0.05), which was accompanied by an increase in the total adenine nucleotide pool (TAN; ~19%, P < 0.05) and energy charge [E-C = (ATP + 0.5 ADP)/(ATP + ADP + AMP); ~4%; P < 0.05]. In the EDL, a reduction in the content of the less prevalent type I MyHC protein from ~3% in controls to 0% after clenbuterol treatment (P < 0.05) occurred without any alterations in TAN and E-C. These findings demonstrate that the phenotypic changes previously observed in slow muscle after clenbuterol administration at 1-2 mg·kg body mass-1·day-1 are also observed at a substantially lower dose and are paralleled by concomitant changes in cellular energy metabolism.

KW - β-Adrenoceptor agonist

KW - Adenosine 5'-triphosphate

KW - Energy charge

KW - Myosin heavy chain protein composition

UR - http://www.scopus.com/inward/record.url?scp=0033830095&partnerID=8YFLogxK

M3 - Article

VL - 279

JO - American Journal of Physiology-Regulatory Integrative and Comparative Physiology

JF - American Journal of Physiology-Regulatory Integrative and Comparative Physiology

SN - 0363-6119

IS - 3 48-3

ER -